At last week’s Antibody Engineering & Therapeutics conference in San Diego, CA, iBio (NYSE AMERICAN:IBIO) presented its glycan engineering technologies and plant-based manufacturing platform as a means to rapidly develop and produce bio-betters, such as the bio-better rituximab product candidate it’s currently developing with commercial partner, CC-Pharming.
iBio presented data demonstrating how its FastGlycaneering technology enables greater glycosylation customization and control. In the case of bio-better rituximab, antibody dependent cellular cytotoxicity increased 30-fold and potency was substantially improved, compared with the control antibody.
“This study demonstrated that our complementary glycan engineering technology can improve the activity of therapeutic antibodies, which is instrumental in the development of antibodies with higher potency,” Dr. Sylvain Marcel, iBio’s VP of protein expression sciences, said in a statement.
“These data represent a very positive development within our collaboration with CC-Pharming and, in addition, highlight iBio’s ability to produce antibodies with more homogeneous and humanized glycosylation patterns, which can help our other clients and partners achieve their target product profiles,” he added.
